Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BERGEN BRUNSWIG WHSLE. DRUG BUSINESS GENERATES $1.33 BIL. SALES

Executive Summary

BERGEN BRUNSWIG WHSLE. DRUG BUSINESS GENERATES $1.33 BIL. SALES in fiscal 1984 (ended Aug. 31) not including sales from the firm's two drug whslr. acquisitions in September, Bergen said in its recently released annual report. The annual report notes that Bergen Brunswig's whsle. drug sales increased 17% in fiscal 1984 and accounted for 78% of the firm's total sales -- down from 80% in FY 1983. Operating earnings from the drug div. were up 14% to $47.4 mil., the report adds. Bergen Brunswig's two recent drug whsle. acquisitions, Allen Co. and Synergex with combined sales of $400 mil., put the firm well over the $2 bil. mark in terms of overall FY 1984 sales and add nearly $310 mil. in sales to Bergen's drug div. Following the pending merger of Bergen Brunswig with Natl. Intergroup (formerly Natl. Steel), the drug div. will represent roughly one-third ($1.33 bil.) of the newly formed Bergen Natl.'s revenues of nearly $4 bil. based on FY 1984 performances ("The Pink Sheet" Oct. 8, p. 8). If the Synergex acquisition is completed, the drug div. will represent roughly 40% ($1.64 bil.) of Bergen Natl.'s business. However, Bergen Brunswig's planned acquisition of Synergex may be threatened due to resistance to the merger from the Justice Dept. In a joint release on Nov. 13, Bergen and Synergex reported that Justice had filed a request with the two companies seeking further information on the proposed acquisition. "The effect of the request is to extend the waiting period during which the parties may not effect the acquisition for 20 days from the date Synergex and Bergen Brunswig fully respond to the division's request," the release explains. Both whslrs. said they intend to respond "as soon as possible." The transaction is currently scheduled to close on Jan. 2, 1985 but is subject to the expiration of the Hart-Scott-Rodino waiting period; to approval by Synergex shareholders; and "to certain other closing conditions," the release notes. While waiting for Justice's final word on the Synergex acquisition, Bergen can take some solace in the performance of its Commtron consumer electronics distribution business. Purchased in 1982, Commtron moved ahead of Bergen's med/surgical div. in fiscal 1984 and is now the whslr.'s second largest business in terms of sales. Commtron sales in fiscal 1984 rose 72% to $210.4 mil., while operating earnings jumped 60% to $6.3 mil. The FY 1984 sales level represents more than a threefold increase in sales in the two years since Commtron was acquired by Bergen.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

LL1133833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel